
Persephone Biosciences is a synthetic biology company focused on reimagining patient and infant health by repairing damaged human ecosystems. They are developing an industrialized approach to engineer cells to restore health, addressing issues like disease progression, therapeutic response, nutrition, and longevity. The company is actively involved in clinical studies and has announced collaborations, such as with Kroger Health for the AMBROSIA Food as Medicine Study, and with Ginkgo Bioworks on a reusable bacteriocentes anaerobic engineering toolkit. Their work aims to create microbial products that positively impact health outcomes.

Persephone Biosciences is a synthetic biology company focused on reimagining patient and infant health by repairing damaged human ecosystems. They are developing an industrialized approach to engineer cells to restore health, addressing issues like disease progression, therapeutic response, nutrition, and longevity. The company is actively involved in clinical studies and has announced collaborations, such as with Kroger Health for the AMBROSIA Food as Medicine Study, and with Ginkgo Bioworks on a reusable bacteriocentes anaerobic engineering toolkit. Their work aims to create microbial products that positively impact health outcomes.
Founded: 2017
Headquarters: San Diego, California
Focus: Synthetic biology and microbiome-based therapeutics for patient and infant health
Recent funding: $15.12M total (latest seed Jul 19, 2022)
Founders / leadership: Stephanie Culler (Co‑founder & CEO), Steve Van Dien (Co‑founder & CTO)
Microbiome therapeutics and engineered cell-based interventions for human health
2017
Biotechnology
$15,000,000
Reported seed financing in 2022
Prior early-stage round listed on company profiles
Early financing activity listed on company profiles
“Investors include Y Combinator, Susa Ventures, First Bight Ventures, Propel Bio Partners, North South Ventures, Fifty Years, Ocampo Capital, ZhenFund, Pioneer Fund, BrightEdge Fund”